Clinical Trial Update: Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pralatrexate for relapsed or refractory B-cell non-Hodgkin's lymphoma has completed, with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Or Refractory B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Pralatrexate (pralatrexate)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Lymphoma, B-Cell | Phase 2 | Status: COMPLETED | Results posted: 2021-11-05